UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
OpenAI Restricts Astra AI Over Cyberattack Risks 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Airbus Joins Air India A320 Altitude Drop Probe 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
AstraZeneca’s experimental pill camizestrant significantly reduced the risk of disease progression or death in hormone receptor-positive, HER2-negative breast cancer, according to new data presented at the American Society of Clinical Oncology (ASCO) meeting. In the trial, patients switched to camizestrant after early signs of resistance detected through a blood-based liquid biopsy showed a 56% improvement in progression-free survival compared to standard therapy.
This marks the first time liquid biopsy has been used to guide treatment decisions before visible tumor growth. Dr. Eleonora Teplinsky of Valley-Mount Sinai said the early switch approach allows oncologists to “stay ahead of the curve,” potentially changing how breast cancer is treated.
The phase 3 study enrolled 3,256 women with advanced HR-positive, HER2-negative breast cancer. After at least six months of aromatase inhibitors and CDK4/6 inhibitors—like Kisqali (Novartis), Ibrance (Pfizer), or Verzenio (Eli Lilly)—315 patients with ESR1 mutations were identified and randomized. Patients receiving camizestrant plus a CDK4/6 inhibitor saw a median of 16 months without disease progression, versus 9.2 months on standard therapy with placebo.
No new safety issues were reported, and dropout rates remained low. Camizestrant is a selective estrogen receptor degrader (SERD), designed to block estrogen signaling in cancer cells—an alternative when standard hormone therapies lose effectiveness.
In a separate trial, AstraZeneca’s immunotherapy Imfinzi (durvalumab), combined with FLOT chemotherapy, reduced the risk of disease recurrence or death by 29% in early-stage gastric and esophageal cancer patients. The findings support earlier intervention with immunotherapy and are expected to influence global treatment practices.
AstraZeneca CEO Pascal Soriot emphasized the importance of proactive monitoring, calling it the future of cancer care. Both studies were simultaneously published in the New England Journal of Medicine.
